$RMD (RESMED) — 8-K: RMD Q1 FY27: Adj EPS $2.91 beats street by $0.24 (+8.9%); revenue $1.415B +5.9% YoY

Resmed delivered a clean beat, with adjusted EPS of $2.91 topping the $2.67 consensus by $0.24 (+8.9%). Revenue came in at $1.415B, up 5.9% YoY (7% core constant currency), while FY2027 guidance was maintained at adjusted EPS of $12.00-$12.25 and revenue of $5.8B-$5.8B. Top-line strength was driven by strong demand across sleep devices and masks and accessories, with non-GAAP gross margin expanding 50 basis points to 62.5% on productivity pipeline execution.

Resmed delivered a clean beat, with adjusted EPS of $2.91 topping the $2.67 consensus by $0.24 (+8.9%). Revenue came in at $1.415B, up 5.9% YoY (7% core constant currency), while FY2027 guidance was m